{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:30:30Z","timestamp":1764084630376},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,15]]},"DOI":"10.7759\/cureus.22229","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T13:59:51Z","timestamp":1644933591000},"source":"Crossref","is-referenced-by-count":1,"title":["Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis Presenting With Severe Abdominal Pain Mimicking Acute Peritonitis"],"prefix":"10.7759","author":[{"given":"Qianwen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangze","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/PHAR.1010","article-title":"Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"32","author":"Shah NK","year":"2012","unstructured":"Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2012, 32:80-94. 10.1002\/PHAR.1010","journal-title":"Pharmacotherapy"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020228","article-title":"Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: a case report","volume":"99","author":"Lee IH","year":"2020","unstructured":"Lee IH, Ahn DJ. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: a case report. Medicine (Baltimore). 2020, 99:e20228. 10.1097\/MD.0000000000020228","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231104","article-title":"Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis","volume":"12","author":"Leader R","year":"2019","unstructured":"Leader R, Cowen J, Rajeev SP. Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis. BMJ Case Rep. 2019, 12:10.1136\/bcr-2019-231104","journal-title":"BMJ Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6089","article-title":"Dapagliflozin-induced late-onset euglycemic diabetic ketoacidosis","volume":"11","author":"Iqbal I","year":"2019","unstructured":"Iqbal I, Hamid M, Khan MA, Kainat A, Tariq S. Dapagliflozin-induced late-onset euglycemic diabetic ketoacidosis. Cureus. 2019, 11:e6089. 10.7759\/cureus.6089","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2017.10.001","article-title":"Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a\u00a0case report","volume":"54","author":"Brown F","year":"2018","unstructured":"Brown F, McColl T. Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a\u00a0case report. J Emerg Med. 2018, 54:109-11. 10.1016\/j.jemermed.2017.10.001","journal-title":"J Emerg Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14297","article-title":"Post-operative euglycemic diabetic ketoacidosis in a patient with SGLT-2 inhibitor use and recent sleeve gastrectomy","volume":"13","author":"Smith A","year":"2021","unstructured":"Smith A, Holtrop J, Sadoun M. Post-operative euglycemic diabetic ketoacidosis in a patient with SGLT-2 inhibitor use and recent sleeve gastrectomy. Cureus. 2021, 13:e14297. 10.7759\/cureus.14297","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1764532","article-title":"Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment","volume":"19","author":"Sampani E","year":"2020","unstructured":"Sampani E, Sarafidis P, Papagianni A. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment. Expert Opin Drug Saf. 2020, 19:673-82. 10.1080\/14740338.2020.1764532","journal-title":"Expert Opin Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/2042018816676239","article-title":"The renal effects of SGLT2 inhibitors and a mini-review of the literature","volume":"7","author":"Andrianesis V","year":"2016","unstructured":"Andrianesis V, Glykofridi S, Doupis J. The renal effects of SGLT2 inhibitors and a mini-review of the literature. Ther Adv Endocrinol Metab. 2016, 7:212-28. 10.1177\/2042018816676239","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon S","year":"2019","unstructured":"Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019, 79:1135-46. 10.1007\/s40265-019-01148-3","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor SI","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015, 100:2849-52. 10.1210\/jc.2015-1884","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03188.x","article-title":"Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA","volume":"95","author":"Nair S","year":"2000","unstructured":"Nair S, Yadav D, Pitchumoni CS. Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. Am J Gastroenterol. 2000, 95:2795-800. 10.1111\/j.1572-0241.2000.03188.x","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/PAF.0000000000000248","article-title":"Gastric mucosal petechial hemorrhages (Wischnewsky lesions), hypothermia, and diabetic ketoacidosis","volume":"37","author":"Clark KH","year":"2016","unstructured":"Clark KH, Stoppacher R. Gastric mucosal petechial hemorrhages (Wischnewsky lesions), hypothermia, and diabetic ketoacidosis. Am J Forensic Med Pathol. 2016, 37:165-9. 10.1097\/PAF.0000000000000248","journal-title":"Am J Forensic Med Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/81752-dapagliflozin-associated-euglycemic-diabetic-ketoacidosis-presenting-with-severe-abdominal-pain-mimicking-acute-peritonitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:18Z","timestamp":1707507438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/81752-dapagliflozin-associated-euglycemic-diabetic-ketoacidosis-presenting-with-severe-abdominal-pain-mimicking-acute-peritonitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.22229","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}